Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umifenovir add-on therapy versus hydroxychloroquine alone for outpatient COVID-19
IRCT20200523047550N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of umifenovir and hydroxychloroquine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Cough, Fever and 5 more. Started Apr 2020; status: completed.
02
Drugs
umifenovirhydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200523047550N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200523047550N1.